People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RedHill Biopharma Ltd. | — | Pharmaceuticals | Series C | $72.5M | $101.6M | 2021 |
| NeuBase Therapeutics, Inc. | — | Biotechnology | Series A | $17.1M | $42.7M | 2013 |
June Almenoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside June Almenoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dov Goldstein | 1 | 6 |
| Dietrich Stephan | 1 | 4 |
| Ira Greenstein | 1 | 3 |
| Kenneth Reed | 1 | 2 |
| Thomas Riedhammer | 1 | 2 |
| Irach Taraporewala | 1 | 2 |
| GILEAD RADAY | 1 | 2 |
| Shmuel Cabilly | 1 | 2 |
| Alla Felder | 1 | 2 |
| Rick D Scruggs | 1 | 2 |
| Eric Richman | 1 | 2 |
| Franklyn Prendergast | 1 | 2 |
| Adi Frish | 1 | 1 |
| Ofer Tsimchi | 1 | 1 |
| Ori Shilo | 1 | 1 |
| Dror Ben Asher | 1 | 1 |
| Guy Goldberg | 1 | 1 |
| Uri Hananel Aharon | 1 | 1 |
| Dan Suesskind | 1 | 1 |
| Andrew Limpert | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.